Refinement of lower acceptance value of the similarity factor f2 incomparison of dissolution profiles

Dissolution Technologies

Volumn 9, Issue 1, 2002, Pages 18-22

  Gohel, Mukesh C ^a   Panchal, Maulik K ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DISSOLUTION; DRUG INDUSTRY; MARKETING;

EID: 84962091049     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT090102P18     Document Type: Article

References (17)

1. J. Swarbrick, "In vitro dissolution, drug bioavailability and the spiral of science," Pharmaceutical Technology 21 (6):68-72 (1997)
2. Guidance for industry: Immediate release solid oral dosage forms:Scale-up and post-approval changes (SUPAC-IR): Chemistry, Manufacturing and Controls, In vitro dissolution testing,and in vivo bioequiva-lence documentation.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, November 1995.
3. Guidance for Industry: Modified release solid oral dosage forms: Scale-up and post-approval changes (SUPAC-MR):Chemistry, Manufacturing and Controls; In vitro dissolution testing, and in vivo bioequivalence documentation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, September 1997.
4. L.J. Leeson, "In vitro / in vivo correlation," Drug Information Journal 29:903-915 (1995)
5. U.V. Banakar, "Pharmaceutical Dissolution Testing, In: Drug and the Pharmaceutical Sciences," Swarbrick J. (Ed.),Volume 49, Marcel Dekker, New York,p-407,1992
6. J.W. Moore, and H. H. Flanner, "Mathematical comparison of dissolution profiles," Pharmaceutical Technology 20 (6):64-74 (1996)
7. Guidance for Industry:Dissolution testing of immediate release solid oral dosage forms, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,August 1997.
8. Guidance for Industry: Extended release oral dosage forms: Development, evaluation and application of in vitro/in vivo correlations, U S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,September 1997.
9. Human Medicines Evaluation Unit, EMEA, Notes for guidance on quality of modified release products:A. Oral dosage forms; B.Transdermal dosage forms;Section I (Quality),1999.
10. V.P. Shah et al., "In-vitro dissolution profile comparison-Statistics and analysis of the similarity factor f2," Pharmaceutical Research 15(6):889-896 (1998)
11. Guidance:Oral extended (controlled) release dosage forms, In vivo bioequivalence and in vitro dissolution testing, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, September 1997.
12. Guidance for Industry: BA and BE studies fo r orally administered drug products, General considerations, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, August 1999.
13. M.C. Gohel, and M.K. Panchal, "Comparison of in vitro dissolution profiles using a novel, model-independent approach" Pharmaceutical Technology 24 (3):92-102 (2000)
14. M.C. Gohel, and M.K. Panchal, "Novel use of similarity factors f2 and Sd for the development of diltiazem HCl modified release tablets using a 32 factorial design", Drug Development and Industrial Pharmacy 28(1):77-87 (2001)
15. M.C. Gohel et al., "Novel mathematical method for quantitative expression of deviation from the Higuchi model" AAPS Pharm Sci Tech 1 (4):article 31 (2000)
16. J. E. Pollietal., "Methods to compare dissolution profiles and a rationale for wide dissolution specification for metoprolol tartrate tablets" Journal of Pharmaceutical Sciences 86 (6):690-700 (1997)
17. N. Yuksel et al., "Comparison of in vitro dissolution profiles by ANOVA-based, model-dependentand -independent methods" International Journal of Pharmaceutics 209:57-67 (2000)